GnRH-a联合优思明对子宫腺肌症行宫腔镜子宫内膜电切术治疗疗效影响和安全性评价

doi:10.3969/j.issn.1006-6233.2022.08.014

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (1182 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the efficacy and safety of GnRH-a combined with ursamine in the treatment of adenomyosis by hysteroscopic endometrial resection.Methods: 107 patients with adenomyosis treated in our hospital from March 2016 to March 2021 were selected and randomly divided into control group (53 cases, subcutaneous injection of 3.75mg GnRH-a, once / 4 weeks, a total of 3 months) and observation group (54 cases, subcutaneous injection of 3.75mg GnRH-a, once / 4 weeks + ursamine, 1 tablet/time, stopped for 7 days after 21 days, a total of 3 months). The pain score, uterine volume, menstrual volume, and ovarian function were counted before operation and 3 months after treatment. The clinical efficacy after 3 months of treatment and adverse reactions during treatment were counted. The recurrence within 12 months was counted. Results After 3 months of treatment, the levels of vas, uterine volume, PBAC, FSH, and LH in the observation group were lower than those in the control group (P<0.05). The curative effect of the observation group was better than that of the control group (P<0.05). The total incidence and recurrence rate of adverse reactions in the observation group were lower than those in the control group (P<0.05). Conclusion: The follow-up treatment of adenomyosis with GnRH-a combined with ursamine after hysteroscopic endometrial resection is effective, which effectively alleviates the degree of dysmenorrhea, and restores ovarian function, reduces the incidence of postoperative adverse reactions, and reduces the recurrence rate to a certain extent.

Key words： Yousiming Adenomyosis Hysteroscopy Gonadotropin-releasing hormone agonist Electroresection of endometrium

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Yuanyuan
	ZHANG Lei
	YANG Yijun

Cite this article:

ZHU Yuanyuan,ZHANG Lei,YANG Yijun. Evaluation of the Efficacy and Safety of GnRH-a in Combination with Ursamine in the Treatment of Adenomyosis by Hysteroscopic Endometrial Electrosurgery[J]. HeBei Med, 2022, 28(8): 1303-1306.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2022.08.014 OR http://www.hbyxzzs.cn/EN/Y2022/V28/I8/1303

[1] 李娟清,黄秀峰,石一复.医源性子宫腺肌症[J].中国实用妇科与产科杂志,2021,37(10):13-17.
[2] 郭明华,邓增梅,徐红.曼月乐联合促性腺激素释放激素激动剂治疗子宫腺肌症的临床研究[J].广西医科大学学报,2020,37(3):24-28.
[3] 张爱凤,陈富强.宫腔镜下子宫内膜切除术联合曼月乐治疗子宫腺肌病的临床效果分析[J].贵州医药,2020,44(7):2-7.
[4] 尚梦玲.子宫内膜电切术后放置左炔诺孕酮宫内节育系统在子宫腺肌症治疗中的效果观察[J].实用中西医结合临床,2021,21(6):2-6.
[5] 郭明华,邓增梅,徐红.曼月乐联合促性腺激素释放激素激动剂治疗子宫腺肌症的临床研究[J].广西医科大学学报,2020,37(3):134-138.
[6] 徐键.妇产科常见疾病诊治指南[M].杭州,浙江大学出版社,2010.41-43.
[7] Sung YT,Wu JS.The Visual Analogue Scale for Rating,Ranking and Paired-Comparison (VAS-RRP):A new technique for psychological measurement[J].Behav Res Methods,2018,50(4):1694-1715.
[8] Ko JKY,Lao TT,Cheung VYT.Pictorial Blood Loss Assessment Chart for evaluating heavy menstrual bleeding in Asian women[J].Hong Kong Med,2021,27(6):399-404.
[9] 孙海娇,朱艳.丹莪妇康煎膏联合GnRH-a对子宫腺肌症患者子宫内膜容受性的影响[J].中国妇幼保健,2020,35(8):54-58.
[10] 王丽娟,汤春辉.GnRH-a联合左炔诺孕酮宫内缓释系统对子宫腺肌症患者疼痛症状,血清MMPs及复发的影响[J].中国计划生育学杂志,2021,29(2):6-10.
[11] 任娟.HIFU联合GnRH-α对子宫腺肌病的治疗及预后影响分析[J].安徽医药,2020,10(1):18-21.
[12] 徐春晓,康程,高伟佳.优思明治疗子宫内膜异位症的疗效与不良反应[J].西部医学,2021,33(1):14-17.
[13] 张青松,王妮.优思明在促进无痛人工流产术后患者月经转归及子宫内膜增长中的应用效果[J].当代医药论丛,2021,19(22):122-123.